Skip to main content
SpringerLink
Log in

Principles of Chemotherapy for Genitourinary Cancer

  • Chapter
Urological Oncology

Abstract

Cytotoxic chemotherapy evolved from the concepts of Lissauer and Ehrlich early in the 20th century. The initial chemotherapy protocols were characterized by a lack of specificity, often with significant toxicity to the host. This has been subsequently improved due to a better understanding of tumor biology, the basis of the cell cycle and constituency of the human genome, and the biochemical basis of action of the chemotherapy regimens. In the past century, insight into the intracellular pathways that result in sensitivity and resistance of the neoplastic cells to drug treatment have led to significant refinement of our technology, leading to more effective and less toxic treatment regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tannock IF. Cell kinetics and chemotherapy. A critical review. Cancer Treat Rep 1978;62:1117–1133.

    CAS  PubMed  Google Scholar 

  2. Young RC, De Vita VT. Cell cycle characteristics of human solid tumors in vivo. Cell Tissue Kinet 1970;3:285–290.

    CAS  PubMed  Google Scholar 

  3. Alberts DS. A unifying vision of cancer therapy for the 21st century. J Clin Oncol 1999;17(11 suppl);13–21.

    CAS  PubMed  Google Scholar 

  4. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XII: on the criteria and kinetics associated with “curability of leukemia.” Cancer Chemother Rep 1964;35:1–111.

    CAS  PubMed  Google Scholar 

  5. Yankee RA, De Vita VT, Perry S. The cell cycle of leukemia L1210 cells in vivo. Cancer Res 1968;27:2381–2385.

    Google Scholar 

  6. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986; 314:1423–1431.

    CAS  PubMed  Google Scholar 

  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  8. Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 1989;28:113–121.

    Article  CAS  PubMed  Google Scholar 

  9. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–1416.

    CAS  PubMed  Google Scholar 

  10. Nowell PC. The clonal evolution of tumor progression. Science 1976;194:23–28.

    Article  CAS  PubMed  Google Scholar 

  11. Nowell P. Mechanisms of tumor progression. Cancer Res 1986;46:2203–2207.

    CAS  PubMed  Google Scholar 

  12. Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987;14(suppl):29–33.

    CAS  PubMed  Google Scholar 

  13. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163–169.

    CAS  PubMed  Google Scholar 

  14. Norton LA. A gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067–7071.

    CAS  PubMed  Google Scholar 

  15. Newell DR, McLeod HL, Schellens JHM. The pharmacology of anticancer drugs. In: Souhami RL, Tannock I, Hohenberger PF, Horiot J-C, eds. Oxford Textbook of Oncology, 2nd ed. London: Oxford University Press, 2002:623–637.

    Google Scholar 

  16. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590–2611.

    CAS  PubMed  Google Scholar 

  17. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualization in cancer chemotherapy. Drugs 1998;56:1019–1036.

    Article  CAS  PubMed  Google Scholar 

  18. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34:1493–1499.

    Article  CAS  PubMed  Google Scholar 

  19. Ratain M J, Schilisky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8:1739–1753.

    CAS  PubMed  Google Scholar 

  20. Frei E III. Curative cancer chemotherapy. Cancer Res 1985;45:6523–6537.

    PubMed  Google Scholar 

  21. Krakoff IH. Systemic treatment of cancer. CA Cancer J Clin 1996;46:134–141.

    Article  CAS  PubMed  Google Scholar 

  22. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu RevBiochem 1989;58:137–171.

    Article  CAS  Google Scholar 

  23. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human tumors. J Natl Cancer Inst 1989;81:116–124.

    Article  CAS  PubMed  Google Scholar 

  24. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32A: 921–926.

    Article  CAS  PubMed  Google Scholar 

  25. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127–137.

    Article  CAS  PubMed  Google Scholar 

  26. Moolgavkar SH, Knudsen AG. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981;66:1037–1052.

    CAS  PubMed  Google Scholar 

  27. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344–354.

    CAS  PubMed  Google Scholar 

  28. Pendyala L, Velagapudi S, Toth L, et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997;3:793–798.

    CAS  PubMed  Google Scholar 

  29. Fearon EC. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043–1058.

    Article  CAS  PubMed  Google Scholar 

  30. Sikic BL. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11:1629–1635.

    CAS  PubMed  Google Scholar 

  31. De Vita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;228:998–1006.

    Article  Google Scholar 

  32. Skipper HE. Critical variables in the design of combination chemotherapy regimens to be used alone or in adjuvant settings. Colloque INSERM 1986;137:11.

    Google Scholar 

  33. Hyrniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987:14:65–74.

    Google Scholar 

  34. Day RS Treatment sequencing, asymmetry and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986;46:3876–3880.

    CAS  PubMed  Google Scholar 

  35. Raghavan D, Weiner JS, Lipson L. Cancer in the elderly. In: Souhami RL, Tannock I, Hohenberger PF, Horiot J-C, eds. Oxford Textbook of Oncology, 2nd ed. London: Oxford University Press, 2002:863–874.

    Google Scholar 

  36. Raghavan D, Brandes LJ, Klapp K, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol 2005; 174: 1808–1813.

    Article  CAS  PubMed  Google Scholar 

  37. Bolwell BJ. Factors predicting success or failure associated with common types of transplants. Pediatr Transplant 2005;9:2–11.

    Article  PubMed  Google Scholar 

  38. Margolin K. High dose chemotherapy and stem cell support in the treatment of poor-risk germ cell cancer. In: Raghavan D, ed. American Cancer Society Atlas of Clinical Oncology—Germ Cell Tumors. London: BC Decker, 2003:168–181.

    Google Scholar 

  39. Socie G, Stone JV, Wingard JR, et al. Long term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 1999;341:14–21.

    Article  CAS  PubMed  Google Scholar 

  40. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:2208–2214.

    Article  CAS  PubMed  Google Scholar 

  41. Perry MC, ed. The Chemotherapy Sourcebook, 3rd ed. Baltimore: Williams & Wilkins, 2001.

    Google Scholar 

  42. Kalmadi S, Raghavan D. Fundamentals of cancer treatment—effects of chemotherapy on neoplastic cells. In: McLain R, ed. Current Clinical Oncology: Cancer in the Spine—Comprehensive Care. Totowa, NJ: Humana Press, 2005:31–42.

    Google Scholar 

  43. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408–9421.

    Article  CAS  PubMed  Google Scholar 

  44. Bergsland EK. When does the presence of the target predict response to the targeted agent? J Clin Oncol 2006;24:213–215.

    Article  CAS  PubMed  Google Scholar 

  45. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormonerefractory prostate cancer. Cancer 2006;106:1917–1924.

    Article  CAS  PubMed  Google Scholar 

  46. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002; 2:795–803.

    Article  CAS  PubMed  Google Scholar 

  47. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389–4400.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematologic Oncology and Solid Tumor Oncology Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Sujith Kalmadi MD

  2. Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Derek Raghavan MD, PhD, FACP, FRACP

Authors
  1. Sujith Kalmadi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek Raghavan MD, PhD, FACP, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Bartholomew’s and Homerton Hospitals Queen Mary Barts and the London School of Medicine and Dentistry, University of London, London, UK

    Vinod H. Nargund PhD, FRCS (Urol), FEBU (Chair, Uro-Oncology MDT and Consultant Urological Surgeon) (Chair, Uro-Oncology MDT and Consultant Urological Surgeon)

  2. Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Derek Raghavan MD, PhD, FACP, FRACP (Chairman and Director) (Chairman and Director)

  3. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA

    Howard M. Sandler MD (Professor and Senior Associate Chair) (Professor and Senior Associate Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Kalmadi, S., Raghavan, D. (2008). Principles of Chemotherapy for Genitourinary Cancer. In: Nargund, V.H., Raghavan, D., Sandler, H.M. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-1-84628-738-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-738-1_9

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-387-1

  • Online ISBN: 978-1-84628-738-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation